What is the exclusivity period for orphan drugs?
The exclusivity granted to orphan drugs provides seven years without generic competition for the approved orphan designation but does not prevent generic competition for other approved uses of the medicine.
What drugs are considered orphan drugs?
List of FDA Orphan Drugs
- Acquired hemophilia A.
- Acral lentiginous melanoma.
- Acromegaly.
- Acute intermittent porphyria.
- Acute lymphoblastic leukemia.
- Acute myeloid leukemia.
- Acute promyelocytic leukemia.
- Adenosine deaminase deficiency.
What is orphan market exclusivity?
Market exclusivity is an orphan incentive awarded by the European Commission to a specific clinical indication with an orphan designation. Each indication with an orphan designation confers ten years’ market exclusivity for the particular indication.
How many Orphan drugs are currently on the market today?
Currently, more than 400 orphan designated drugs are commercially available in the marketed and close to 1000 drugs are undergoing clinical trials.
How does FDA exclusivity work?
Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements. A new drug application (NDA) or abbreviated new drug application (ANDA) holder is eligible for exclusivity if statutory requirements are met.
What are orphan products/drugs?
GARD has information from the Food and Drug Administration (FDA) on treatments approved for rare diseases, known as orphan products/drugs. The Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare diseases. The FDA Office of Orphan Products Development determines…
What is the FDA 4035 orphan drug designation request form?
The FDA Orphan Designation Request Form (FDA 4035) is designed to assist sponsors in providing the required content of the orphan drug designation request completely and succinctly.
Does product formulation affect Orphan Drug Designation status?
Orphan drug designation is generally conferred to the active moiety rather than the product formulation; therefore, changes to the product formulation should not generally affect orphan drug designation status. The first sponsor to bring an active moiety to market receives the benefits of exclusivity if that sponsor has orphan designation.
What is an appropriate orphan subset for highly toxic drugs?
Therefore, those patients who are refractory to, or intolerant of, other less toxic drugs may be considered an appropriate orphan subset for purposes of orphan drug designation of the highly toxic drug.